Tazbentetol for people with ALS (expanded access)
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This program provides tazbentetol, an experimental medicine, to people with ALS who cannot join other clinical trials. It aims to make the drug available while more research is done.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with ALS.
- You cannot take part in other interventional clinical trials for ALS.
- Your breathing test (vital capacity) is more than 35% of the normal value for your age, height, and sex.
- If you are currently on standard ALS treatment, you have been on a steady dose for at least 30 days before starting this study drug.
- You are not currently taking another experimental treatment for ALS.
- You are able to swallow pills reliably every day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if tofersen, a drug that targets a protein linked to ALS, can help people who have ALS but do not have mutations in the SOD1 or FUS genes. It aims to slow disease progression in those diagnosed within the last 2 years.
This study tests a non-invasive brain stimulation technique (called transcutaneous spinal direct current stimulation and transcranial magnetic stimulation) to see if it can calm overactive nerves in people with ALS. You may be a good fit if you have ALS that started less than 3 years ago and your breathing is still strong.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This trial tests a new drug, CTx1000, for people with ALS. It aims to see if the drug is safe and tolerable, and may offer a new treatment option.
This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.
This Phase 2 study tests tideglusib to see if it helps slow or improve amyotrophic lateral sclerosis (ALS). You may be eligible if you have early-stage ALS with preserved breathing ability and certain stable treatments.
Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.